Blocking Thrombin Significantly Ameliorates Experimental Autoimmune Neuritis

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Peripheral nerve inflammatory diseases like Guillain-Barré syndrome (GBS) involve complex mechanisms.
• The role of the thrombin and protease-activated receptor 1 (PAR1) pathway in these conditions is not fully understood.

Purpose of the Study:

• To investigate the involvement of the thrombin-PAR1 pathway in experimental autoimmune neuritis (EAN), a rat model of GBS.
• To evaluate the therapeutic potential of inhibiting the thrombin-PAR1 pathway in EAN.

Main Methods:

• EAN was induced in rats using bovine peripheral myelin and complete Freund's adjuvant.
• Thrombin activity was measured in sciatic nerves.
• Rats were treated with thrombin inhibitors (TLCK or NAPAP) or vehicle.
• Clinical scores, rotarod performance, nerve conduction studies, and sciatic nerve histology were assessed.

Main Results:

• Elevated thrombin activity was observed in the sciatic nerves of EAN rats compared to controls.
• Thrombin inhibitors (TLCK and NAPAP) significantly improved clinical and rotarod scores.
• Nerve conduction velocity and distal amplitude were impaired in EAN rats but improved with TLCK treatment.
• TLCK treatment prevented structural damage in the sciatic nerve's node of Ranvier.

Conclusions:

• The thrombin-PAR1 pathway is implicated in the pathogenesis of EAN.
• Inhibition of thrombin-PAR1 signaling demonstrates therapeutic potential for GBS.
• Targeting the thrombin-PAR1 pathway could be a promising strategy for treating GBS and related peripheral neuropathies.